ArticleJournal of microbiology and biotechnology2025
Schisandrin C Improves Chronic Stress-Induced Dyslipidemia in Mice by Regulating Pyroptosis and Autophagy Levels.
Article in Journal of microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic stress emerges as a significant risk factor for metabolic disorders, including hyperlipidemia and fatty liver disease. Schisandrin C (SchC), an essential component of Schisandra chinensis lignans, is known to possess lipid-lowering and liver-protective properties. However, the precise mechanisms underlying its action remain incompletely understood. We hypothesized that SchC exerts a protective effect on chronic stress-induced dyslipidemia in mice by modulating hepatic autophagy and pyroptosis. In this study, a dual model was established for 12 weeks, combining chronic stress with a high-fat diet (HFD). SchC or simvastatin were given respectively starting at week 10. Blood, epididymal white adipose tissue and liver were collected for further analysis. Behavioral tests and lipid levels showed that the dual model construction of HFD and chronic stress used in this study was successful in placing mice in a stressful environment and triggering dyslipidemia. SchC intervention effectively impeded the accumulation of eWAT and reduced the increased lipid levels in mice induced by chronic stress. The expression levels of the pyroptosis marker Caspase-1 and other inflammatory factors NLRP3, IL-1β, and IL-18 were significantly reduced in the liver tissues of chronically stressed mice under SchC treatment. Additionally, SchC significantly reduced expression levels of autophagy-related factors such as Beclin-1, the LC3-B/A ratio, P62, and markers related to the autophagy pathway (PI3K/AKT/mTOR). SchC effectively improves dyslipidemia through various pathways including inhibiting the PI3K/AKT/mTOR pathway, promoting autophagy, reducing pyroptosis. This provides a solid theoretical foundation for the clinical application of SchC in the treatment of dyslipidemia and related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.